Cesca Therapeutics Up 25%: New Medicare Developments Explain Why

In a press release issued by Globe Newswire, Cesca Therapeutics Inc KOOL announced approval for Medicare coverage for its CLIRST III study. This positive news has caused Cesca’s stock to open 21 percent higher than its closing price on Tuesday.

Cesca CEO Robin Stracey said, “We are very pleased with the CMS's decision to approve our potentially life changing, pivotal clinical study in critical limb ischemia ("CLI") for Medicare reimbursement...Medicare reimbursement will further the Company's efforts to find an effective treatment for CLI, the most severe form of peripheral arterial disease…”

Related Link: Another Visit With A Leveraged Biotech ETF

What The Funding Means

The Medicare funding will allow the company to conduct their clinical trial at a lower cost than previously anticipated. There is a significant unmet demand for CLI treatment, with over 200,000 amputations for chronic foot and leg ulcers occurring each year. Cesca management hopes that the clinical trials will be successful and they can put the treatment to market and reduce these number of amputations.

Cesca Therapeutics was recently seen trading at $0.394, up 9.45 percent.

Image Credit: Public Domain
Posted In: Analyst ColorLong IdeasNewsHealth CareAnalyst RatingsTrading IdeasGeneralCLIRST IIIGlobe NewswireRobin Stracey
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!

Loading...